Bal Pharma share news, announcements and annual reports
NSE: BALPHARMABSE: 524824Pharmaceuticals & BiotechnologySmall Cap
Bal Pharma Limited · Face value ₹10 Face value. The nominal value of one share as the company issued it, the unit its share capital is counted in and a dividend can be stated as a percentage of; it has no link to the share price. Face value in the glossary · Listed Apr 1995 on BSE, May 2006 on NSE
Last close ₹81.85down ₹2.76 (3.26%)BSE ₹81.20
Share price at the NSE close on 30 Oct 2026. Previous close ₹84.61.
30 Oct: open ₹84.05, high ₹84.05, low ₹81.21
52-week range of traded prices to 30 Oct 2026
₹60.00Low, 30 Mar 2026₹124.60High, 10 Sep 2026
- Delivery only: shares bought must be paid for in full, with no selling on the same day.
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies. Market capitalisation: how it is worked out
- ₹130 Cr2,779th largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. Price to earnings, trailing: how it is worked out
- 18.08
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. Price to book: how it is worked out
- 1.58
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- 1.47%
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it.
- 9.0%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet.
- 9.3%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026.
- 1.94
- Volume, NSEVolume. Shares traded on the last trading day. Volume in the glossary
- 6,401
Bal Pharma share news and announcements
549 announcements, routine notices left out, newest first. Page 11 of 11.
Jan 2011
14 Jan · Board meeting
To consider, and take on record, the Unaudited Financial Results for the third quarter, ended on, December 31, 2010.
Nov 2010
Oct 2010
25 Oct · Board meeting
Among other things, the main purpose of the meeting is to consider, and take on record, the Unaudited Financial Results for the 2nd quarter, ended on, September 30, 2010.
Sep 2010
27 Sep · Meeting
Annual General Meeting of the Company was held on September 27, 2010, as scheduled. Ordinary Resolutions approving the followings were passed at the meeting : (1) The audited Balance Sheet as at March 31, 2010 and Profit and Loss Account for the year ended on that date, together with the Directors' Report and Auditor's Report was adopted; (2) Mr. Shrenik Siroya was re-appointed as Director; (3) Dr.G.S.R Subba Rao was re-appointed as Director; (4) Messrs Ostawal & Jain, Auditors of the Company was reappointed and was authorized the Board of Directors to fix their remuneration.
Aug 2010
23 Aug · Meeting
Annual General Meeting of the members of the Company will be held on September 27, 2010. Further the Register of Members and the Share Transfer Books will remain closed on September 27, 2010 for the purpose of the ensuing Annual General Meeting of the Company.
Jul 2010
20 Jul · Board meeting
Among other things, the main purpose of the meeting is to consider, and take on record, the Unaudited Financial Results for the first quarter, ended on, June 30, 2010 and Audited Financial Results for the year ended on March 31, 2010.
Apr 2010
29 Apr · Board meeting
Meeting on 14 May 2010: “Unaudited Financial Results for the qtr ended March 31, 2010”
Mar 2010
30 Mar · Notice of Meeting
By an Order made on February 17, 2010 in the Bal Pharma Limited Application, the Hon'ble High Court of Karnataka at Bangalore has directed a meeting of the Equity Shareholders and Unsecured Creditors of the Applicant/ Transferee company be held on April 08, 2010 for the purpose of considering, and if thought fit, approving with or without modification(s), the Scheme of Amalgamation proposed to be made between Basav Chem Limited (Transferor Company) & Bal Pharma Limited (Transferee Company). A copy of the notice of meeting shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.
Dec 2009
21 Dec · Board meeting
To consider and take on record, the Unaudited Financial Results for the third quarter, ended on December 31, 2009.15 Dec · Meeting
Minutes of the Annual General Meeting of the Company held on September 25, 2009. A copy of the same shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.
Oct 2009
15 Oct · Board meeting
Meeting on 31 Oct 2009: “Unaudited Financial Results for the Qtr ended Sept 30, 2009”
Sep 2009
25 Sep · Meeting
Outcome of Annual General Meeting held on September 25, 2009 : 1) The audited Balance Sheet as at March 31, 2009 and Profit and Loss Account for the year ended on that date, together with the Directors' Report and Auditor's Report was adopted; 2) Dividend @ 7.5% was declared. 3) Dr. S. Prasanna was reappointed as Director. 4) Mr. Arun Bhan was reappointed as Director. 5) Messrs Ostawal & Jain, Auditors of the Company was reappointed and was authorized the Board of Directors to fix their remuneration. 6) Special resolution for appointment and increase in remuneration to Mr. Shailesh Siroya, Managing Director of the Company was approved by the Shareholders.
Jul 2009
28 Jul · Meeting
Register of members & share transfer books of the Company will remain closed from September 22, 2009 to September 25, 2009 (both days inclusive) for the purpose of payment of Dividend for the financial year, 2008-09. The said payment of dividend is subject to the approval of shareholders of the Company at the ensuing Annual General Meeting (AGM) of the Company to be held on September 25, 2009.20 Jul · Board meeting
To consider, and take on record, the unaudited financial results for the first quarter, ended on June 30, 2009, and to discuss the AGM related matters.
Jun 2009
29 Jun · Dividend
Board of Directors, at its meeting held on June 29, 2009 has recommended Dividend of Rs.0.75 per equity share of Rs.10 each.18 Jun · Board meeting
Among other things, to take on record the Audited Financial Results for the year ended on March 31, 2009 and appropriation of profit & recommendation of Dividend if any, for the financial year, 2008-09.
May 2009
29 May · Business
Bal Pharma Limited had informed the Exchange regarding the Board meeting of the Company scheduled on May 28, 2009 . The company has now informed the Exchange that the Board met on May 28, 2009, and among other things, considered and approved the draft Scheme of Amalgamation of Basav Chem Limited (100% subsidiary Company) , with the company in terms of Sections 391 to 394 of the Companies Act, 1956, subject to requisite approvals. The Company proposes to file petition before the Hon'ble High Court of Karnataka for the proposed Amalgamation after 30 days.14 May · Board meeting
Among other things, to take on record the sales performance of the Company, up to March 31, 2009.
Apr 2009
3 Apr · Results
We propose to consider the Audited Financial Results for the year and quarter ended on March 31, 2009 and will publish the Audited results on or before June 30, 2009. Therefore we will not be publishing unaudited results before April 30, 2009.
Feb 2009
5 Feb · Disclosure
None of the Promoter (s) of Bal Pharma Limited has pledged any of the Shareholdings in the Company
Jan 2009
7 Jan · Board meeting
Meeting on 30 Jan 2009: “Unaudited Financial Results for the qtr ended Dec 31, 2008”
Nov 2008
3 Nov · Allotment of Equity Shares
Meeting of the Board of Directors of the Company held on October 27, 2008 has allotted 37,000 equity shares of face value @ Rs. 10/- each, allotted at Rs. 15.75/- per equity share to the eligible employees of the Company under ESOP Scheme, 2006.
Oct 2008
16 Oct · Board meeting
To consider, and take on record, the unaudited financial results for the second quarter, ended on September 30, 2008.
Sep 2008
26 Sep · Meeting
Minutes of the Annual General Meeting of the members of the Company held on September 23, 2008. A copy of the same shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.24 Sep · Meeting
Outcome of the Annual General Meeting of the company held on September 23, 2008. The details of the business transacted at the AGM shall be available on the NSE website (http://www.nseindia.com) under Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.
Aug 2008
12 Aug · Meeting
Register of members and Share Transfer Books of the Company will remain closed from September 11, 2008 to September 23, 2008 (both days inclusive) for the purpose of payment of Dividend for the financial year, 2007-08. The said payment of dividend is subject to the approval of shareholders of the Company at the Annual General Meeting of the Company to be held on September 23, 2008.
Jul 2008
23 Jul · Board meeting
To consider, and take on record, the unaudited financial results for the first quarter, ended on June 30, 2008 and to discuss the AGM related matters.
Jun 2008
24 Jun · Dividend
Board of Directors of the Company at its meeting held on June 23, 2008 has recommended Dividend of 10% per share as against 7.5 % in the previous year.13 Jun · Board meeting
Among other things, to take on record the Audited Financial Results for the year ended on March 31, 2008 and appropriation of profit and declaration of Dividend, for the financial year, 2007-08.
Apr 2008
24 Apr · Board meeting
Board of Directors in their Meeting held on April 18, 2008, took on record the matter that, M/s Basav Chem. Limited, Sangli, Maharashtra, became 100% subsidiary of M/s Bal Pharma Limited, w.e.f. December 06, 2007, and all formalities in this regard had been completed."15 Apr · Board meeting
Company had informed the Exchange regarding a Board Meeting scheduled to be held on April 16, 2008, among other things, to take on record the sales performance of the Company, up to March 31, 2008. The Company has now informed the Exchange that the meeting of the Board of Directors of the Company which was scheduled to be held on April 16, 2008, has been postponed, due to unavoidable circumstances, and the said meeting is rescheduled to be held on April 18, 2008, to transact the business as detailed in the earlier notice.7 Apr · Board meeting
Among other things, to take on record the sales performance of the Company, up to March 31, 2008.7 Apr · Results
Management of the Company has decided to place audited accounts of the Company, instead of the unaudited financial results of the quarter, ended on , March 31, 2008, on or before June 30, 2008. The Company closes its financial year on March 31, 2008.
Feb 2008
25 Feb · News Verification
News Verification : The media had reports on 23rd February, 2008 that Bal Pharma Limited may raise $ 20 million for capacity expansion and asset acquisition. The Exchange, in order to verify the accuracy or otherwise of the information reported in the media and to inform the market place so that the interest of the investors is safeguarded, had written to the officials of the company. Bal Pharma Limited has vide its letter inter-alia stated, "The Company has been allocated 10 acres of land at SEZ , Hassan, Karnataka. The Company is planning to raise 20 million USD for capacity expansion and for acquisition of assets either through Term Loan or ECCB/ECB route. The first phase of expansion will be bulk drug actives with an investment of about 35 crores at Hassan, Karnataka and the balance of the funding will be allocated for expansion of capacities at its existing plants and also scanning the markets for acquisition of assets."18 Feb · Purchase of shares
Mr. Shailesh Siroya, Folio No. IN30113513221436, who is in the list of promoters as on 31st December, 2008 has informed to us on 15th February, 2008 that, he has purchased 6,000 (six thousand only/-) shares of Bal Pharma Limited, on 13-02-2008 @ net rate of Rs.27.83/- (Rupees Twenty seven, and eighty three paise) per share. The Company has taken the information on record. Holding of Mr. Shailesh Siroya, before purchase was 6,52,200, and after purchase were 6,58,200
Jan 2008
11 Jan · Board meeting
Among other things, to take on record the unaudited financial results for the 3rd quarter, ended on December 31, 2007.
Oct 2007
10 Oct · Board meeting
Among other things, to take on record the unaudited financial results for the quarter ended September 30, 2007.8 Oct · Meeting
Proceedings of Annual General Meeting of the Company held on September 20, 2007. A copy of the same shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.
Sep 2007
24 Sep · Meeting
Annual General Meeting of the Company was held on September 20, 2007 as scheduled. Resolutions approving the followings were passed at the meeting. (1) Dividend @ 7.5% was declared. (2) Mr. Arun Bhan was reappointed as Director. (3) Dr. S Prasanna was reappointed as Director. (4) M/s Ostawal & Jain , Auditors of the Company was reappointed and was authorized the Board of Directors to fix their remuneration. (5) The remuneration paid to Mr. A.R. Hegde, Ex-Director & Chief Operating Officer was approved.
Aug 2007
23 Aug · Meeting
The Register of Members & Share Transfer Books of the Company will remain closed from 11th September, 2007 to 20th September, 2007 (both days inclusive) for the purpose of Annual General Meeting (AGM) of the Members of the Company to be held on 20th September, 2007 and for declaration of dividend
Jul 2007
24 Jul · Board meeting
To consider: a) Unaudited financial results for the first quarter ending June 30, 2007. b) To discuss the AGM related matters.5 Jul · Management
Mr.S.Ramji, has been appointed as Company Secretary & Compliance Officer of Bal Pharma Limited, w.e.f. 18.06.2007 in place of Mr.K.Mahadevan, Company Secretary & Compliance Officer.2 Jul · Dividend
Board of Directors at their meeting held on June 30, 2007 has recommended a Dividend of Rs.7.5% per share.
Jun 2007
26 Jun · Board meeting
Among other things, to take on record the audited financial results for the year ended March 31, 2007.11 Jun · Management
Mr. N.D Prabhu, (Independent Director) & Mr. A. R Hegde, (Additional Director), has resigned from the Directorship of Bal Pharma Limited due to personal reasons, w-e-f 01.04.2007 & 30.05.2007. The Meeting of the Board of Directors of the Company held on 31.05.2007-accepted resignations of Mr.N.D Prabhu & Mr. A.R. Hegde
May 2007
31 May · Board meeting
To consideration the routine matters only.24 May · Results
Company shall publish Audited Financial Results within a period of 3 month for the year ended on March 31, 2007 i.e. on or before June 30, 2007.
Mar 2007
21 Mar · Management
Exim Bank of India has appointed Mr. David Rasquinha, General Manager, Exim Bank of India as their Nominee Director on the Board of the company in terms of their Term Loan covenant and he shall hold office at the pleasure of the Exim Bank. His appointment is not taken into account for the number of Directors who retire by rotation
Jan 2007
18 Jan · Board meeting
Among other things, to take on record the unaudited financial results for the quarter ended 31st December, 2006.